

Figure 4. Metastatic adenocarcinoma of the skin with dermal infiltrating glands (H&E, original magnification $\times 100$). The nuclei are highly atypical. The tumor cells are cytokeratin 7 positive, cytokeratin 20 negative, estrogen-receptor positive, and gross cystic disease fluid protein positive, which is consistent with metastasis from a primary carcinoma of the breast (not shown).




Figure 5. Deeply invasive tumor with multiple architectures (sclerosing and nodular) in a case of sclerosing basal cell carcinoma (H&E, original magnification $\times 40$). Basaloid nests without true lumen formation invade subcutaneous adipose tissue.

antigen may be useful in identifying the absence of lumen formation, and Ber-EP4 highlights the epidermal origin of the lesion.⁵




Figure 6. Syringoma is composed of dilated ducts in a fibrotic stroma (H&E, original magnification $\times 40$). Careful microscopic examination would reveal no perineural or deep subcutaneous tumor involvement.

Syringomas most commonly present as multiple small flesh-colored papules on the eyelids. On histology, syringomas present as small superficial dermal lesions composed of small ducts that may form tadpolelike structures in a fibrotic stroma (Figure 6). The ducts are lined by benign cuboidal cells. In contrast to syringoid eccrine carcinomas, syringomas usually present as multiple lesions that are microscopically superficial without perineural involvement.

REFERENCES

1. Sidiropoulos M, Sade S, Al-Habeeb A, et al. Syringoid eccrine carcinoma: a clinicopathological and immunohistochemical study of four cases. *J Clin Pathol.* 2011;64:788-792.
2. Freeman RG, Winkleman RK. Basal cell tumor with eccrine differentiations (eccrine epithelioma). *Arch Dermatol.* 1969;100:234-242.
3. Nishizawa A, Nakanishi Y, Sasajima Y, et al. Syringoid carcinoma with apparently aggressive transformation: case report and review of the literature. *Int J Dermatol.* 2006;45:1218-1221.
4. Urso C, Bondi R, Paglierani M, et al. Carcinomas of sweat glands: report of 60 cases. *Arch Pathol Lab Med.* 2001;125:498-505.
5. Cassarino D. *Diagnostic Pathology: Neoplastic Dermatopathology.* Salt Lake City, UT: Amirsys Publishing Inc; 2012.

Erratum

Due to a submission error, the article “Reduced Degree of Irritation During a Second Cycle of Ingenol Mebutate Gel 0.015% for the Treatment of Actinic Keratosis” (*Cutis.* 2015;95:47-51) contained the incorrect scale for local skin reactions (LSRs). The text in the Methods should have stated:

Using standardized photographic guides, 6 individual LSRs—erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration—were assessed on a scale of 0 (none) to 4 (severe), with higher numbers indicating more severe reactions.

The staff of *Cutis*[®] makes every possible effort to ensure accuracy in its articles and apologizes for the mistake.